JP7391038B2 - Ｔｒｅｇ細胞の抑制特性を増強するための方法 - Google Patents

Ｔｒｅｇ細胞の抑制特性を増強するための方法 Download PDF

Info

Publication number
JP7391038B2
JP7391038B2 JP2020556883A JP2020556883A JP7391038B2 JP 7391038 B2 JP7391038 B2 JP 7391038B2 JP 2020556883 A JP2020556883 A JP 2020556883A JP 2020556883 A JP2020556883 A JP 2020556883A JP 7391038 B2 JP7391038 B2 JP 7391038B2
Authority
JP
Japan
Prior art keywords
tregs
foxp3
cells
tcr
polynucleotide encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020556883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520834A (ja
Inventor
スタウス，ハンス
エル． マクガバン，ジェニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Biomedica PLC
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1806331.3A external-priority patent/GB201806331D0/en
Priority claimed from GBGB1806330.5A external-priority patent/GB201806330D0/en
Application filed by UCL Biomedica PLC, UCL Business Ltd filed Critical UCL Biomedica PLC
Publication of JP2021520834A publication Critical patent/JP2021520834A/ja
Priority to JP2023197319A priority Critical patent/JP7839774B2/ja
Application granted granted Critical
Publication of JP7391038B2 publication Critical patent/JP7391038B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
JP2020556883A 2018-04-18 2019-04-17 Ｔｒｅｇ細胞の抑制特性を増強するための方法 Active JP7391038B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023197319A JP7839774B2 (ja) 2018-04-18 2023-11-21 Ｔｒｅｇ細胞の抑制特性を増強するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1806331.3 2018-04-18
GBGB1806331.3A GB201806331D0 (en) 2018-04-18 2018-04-18 Method
GB1806330.5 2018-04-18
GBGB1806330.5A GB201806330D0 (en) 2018-04-18 2018-04-18 Engineered regulatory T cell
PCT/GB2019/051098 WO2019202323A1 (en) 2018-04-18 2019-04-17 Method for enhancing the suppressive properties of treg cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023197319A Division JP7839774B2 (ja) 2018-04-18 2023-11-21 Ｔｒｅｇ細胞の抑制特性を増強するための方法

Publications (2)

Publication Number Publication Date
JP2021520834A JP2021520834A (ja) 2021-08-26
JP7391038B2 true JP7391038B2 (ja) 2023-12-04

Family

ID=66286535

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020556883A Active JP7391038B2 (ja) 2018-04-18 2019-04-17 Ｔｒｅｇ細胞の抑制特性を増強するための方法
JP2020556864A Active JP7436383B2 (ja) 2018-04-18 2019-04-17 操作された調節性ｔ細胞
JP2023197319A Active JP7839774B2 (ja) 2018-04-18 2023-11-21 Ｔｒｅｇ細胞の抑制特性を増強するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020556864A Active JP7436383B2 (ja) 2018-04-18 2019-04-17 操作された調節性ｔ細胞
JP2023197319A Active JP7839774B2 (ja) 2018-04-18 2023-11-21 Ｔｒｅｇ細胞の抑制特性を増強するための方法

Country Status (11)

Country Link
US (4) US12227756B2 (https=)
EP (2) EP3781672B1 (https=)
JP (3) JP7391038B2 (https=)
KR (1) KR20210003810A (https=)
CN (2) CN112334571B (https=)
AU (2) AU2019254824B2 (https=)
CA (2) CA3105303A1 (https=)
GB (3) GB2611498B (https=)
IL (1) IL278016B2 (https=)
SG (1) SG11202010154UA (https=)
WO (2) WO2019202322A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019254824B2 (en) 2018-04-18 2025-04-24 Ucl Business Ltd Method for enhancing the suppressive properties of Treg cells
EP3921427A1 (en) * 2019-02-05 2021-12-15 Institut National de la Santé et de la Recherche Médicale (INSERM) Recombinant vectors suitable for the treatment of ipex syndrome
GB201915359D0 (en) * 2019-10-23 2019-12-04 Ucl Business Ltd Engineered regulatory t cell
PL241050B1 (pl) * 2019-12-12 2022-07-25 Gdanski Univ Medyczny Zastosowanie limfocytów T regulatorowych jako leku w leczeniu stwardnienia rozsianego
EP4240376B1 (en) * 2020-11-09 2026-03-25 Quell Therapeutics Limited Method for cryopreserving engineered tregs
US20220169687A1 (en) * 2020-11-10 2022-06-02 Kyverna Therapeutics, Inc. Method for treating disease using foxp3+cd4+ t cells
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
US20240400993A1 (en) * 2021-09-27 2024-12-05 Kyoto University Method for producing t cell
US20250017967A1 (en) 2021-12-17 2025-01-16 Quell Therapeutics Limited Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells
US20230210900A1 (en) * 2022-01-04 2023-07-06 Kyverna Therapeutics, Inc. Methods for treating autoimmune diseases
WO2023180690A1 (en) 2022-03-22 2023-09-28 Quell Therapeutics Limited Methods and products for culturing t cells and uses thereof
EP4519417A1 (en) * 2022-05-05 2025-03-12 Quell Therapeutics Limited Method for maintaining suppressive activity of regulatory t cells
CN116284447A (zh) * 2023-02-20 2023-06-23 苏州大学 一种靶向pd1嵌合抗原受体修饰的调节性t细胞及其制备方法与应用
EP4680728A1 (en) 2023-03-17 2026-01-21 Quell Therapeutics Limited Treg therapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
EP1105479B1 (en) 1998-08-11 2011-01-12 Darwin Discovery Limited Identification of the gene causing the mouse scurfy phenotype and its human ortholog
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
US7507542B2 (en) 2001-05-08 2009-03-24 Ucb Sa Method for regulating immune function using the FOXP3 protein
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
WO2005001048A2 (en) 2003-06-13 2005-01-06 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2575604A1 (en) 2004-07-30 2006-02-02 Oregon Health And Science University Methods for detecting and treating autoimmune disorders
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
MX2007014673A (es) 2005-05-24 2008-04-08 Avestha Gengraine Tech Pvt Ltd Metodo para la produccion de un anticuerpo monoclonal para cd20 para el tratamiento de linfoma de celular b.
EP2126054B1 (en) * 2007-01-31 2016-07-06 Yeda Research And Development Company Limited Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
JP5626164B2 (ja) 2011-07-26 2014-11-19 日本精工株式会社 ステアリングコラム用支持装置
US20150073043A1 (en) 2012-01-19 2015-03-12 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Use of phosphorylation pathway-related factor in regulating function of regulatory t cell
RU2523058C2 (ru) 2012-06-29 2014-07-20 Общество с ограниченной ответственностью "Регенекс" Способ терапии ремиттирующего рассеянного склероза
US9693977B2 (en) 2013-03-15 2017-07-04 President And Fellows Of Harvard College Method of increasing the quantity of colonic T regulatory cells via G-coupled protein receptor 43
WO2014183056A1 (en) 2013-05-10 2014-11-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Design and use of specific regulatory t-cells to induce immune tolerance
GB201322430D0 (en) 2013-12-18 2014-02-05 Immunocore Ltd T cell receptors
HK1245827B (en) 2014-12-15 2020-06-19 Board Of Regents Of The University Of Texas System Methods for controlled activation or elimination of therapeutic cells
EP3259284B1 (en) 2015-02-16 2020-04-01 The Trustees of the University of Pennsylvania A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
WO2017058752A1 (en) 2015-09-28 2017-04-06 Trustees Of Dartmouth College Chimeric antigen receptor anti-inflammatory cells and methods of use
WO2017062035A1 (en) 2015-10-09 2017-04-13 Abt Holding Company Methods for enhancing proliferation of t regulatory cells
US10604586B2 (en) 2016-05-09 2020-03-31 Industrial Technology Research Institute Humanized monoclonal antibody and uses thereof
CN109476749A (zh) 2016-06-30 2019-03-15 豪夫迈·罗氏有限公司 改良的过继性t细胞疗法
EP3714944A1 (en) 2019-03-29 2020-09-30 Medizinische Hochschule Hannover Car for use in the treatment of hvg disease
EP3263595A1 (en) * 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
SG11201912010XA (en) 2017-06-12 2020-01-30 Obsidian Therapeutics Inc Pde5 compositions and methods for immunotherapy
WO2018236909A1 (en) 2017-06-20 2018-12-27 La Jolla Institute For Allergy And Immunology Engineered t-cell receptors and methods of their use in modulating inflammatory responses and treating atherosclerosis
EP3697820A4 (en) 2017-10-17 2022-01-05 The General Hospital Corporation PROCEDURES AND COMPOSITIONS RELATED TO MANIPULATED REGULATORY T-CELLS
AU2019254824B2 (en) 2018-04-18 2025-04-24 Ucl Business Ltd Method for enhancing the suppressive properties of Treg cells
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
EP3973067A1 (en) 2019-05-21 2022-03-30 Sangamo Therapeutics, Inc. Controlled transgene expression in regulatory t cells
GB201915359D0 (en) * 2019-10-23 2019-12-04 Ucl Business Ltd Engineered regulatory t cell
GB201915384D0 (en) 2019-10-23 2019-12-04 Ucl Business Ltd Vector
GB202007842D0 (en) 2020-05-26 2020-07-08 Quell Therapeutics Ltd Polypeptide useful in adoptive cell therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Frontiers in Immunology，2017年，Vol. 8，Article 1517, p.1-6
IMMUNOLOGICAL JOURNAL，2015年，Vol.31, No.11，p.951-953
Journal of Neuroinflammation，2012年，Vol. 9, No. 112，p.1-12
Molecular Medicine Reports，2018年02月，Vol.17，p.5860-5868
Proceedings of the National Academy of Sciences，2009年，Vol. 106, No. 45，p.19078-19083

Also Published As

Publication number Publication date
EP3781673A1 (en) 2021-02-24
US20210079425A1 (en) 2021-03-18
SG11202010154UA (en) 2020-11-27
US12227756B2 (en) 2025-02-18
GB2611707A (en) 2023-04-12
KR20210003810A (ko) 2021-01-12
CN112334571A (zh) 2021-02-05
EP3781672B1 (en) 2025-06-18
AU2019254824A1 (en) 2020-11-26
JP7436383B2 (ja) 2024-02-21
IL278016A (en) 2020-11-30
JP7839774B2 (ja) 2026-04-02
WO2019202322A1 (en) 2019-10-24
JP2021520831A (ja) 2021-08-26
US12077774B2 (en) 2024-09-03
GB2611498B (en) 2023-07-19
CA3105303A1 (en) 2019-10-24
AU2019256783A1 (en) 2020-10-22
GB2611498A (en) 2023-04-05
GB202300916D0 (en) 2023-03-08
WO2019202323A1 (en) 2019-10-24
CN112004924A (zh) 2020-11-27
US20250154532A1 (en) 2025-05-15
EP3781672A1 (en) 2021-02-24
GB2587988B (en) 2023-05-31
JP2024026127A (ja) 2024-02-28
JP2021520834A (ja) 2021-08-26
AU2019254824B2 (en) 2025-04-24
GB202018103D0 (en) 2020-12-30
GB2587988A (en) 2021-04-14
US20240384301A1 (en) 2024-11-21
US20210145884A1 (en) 2021-05-20
GB202300872D0 (en) 2023-03-08
IL278016B1 (en) 2024-11-01
CN112334571B (zh) 2024-06-25
CA3098128A1 (en) 2019-10-24
IL278016B2 (en) 2025-03-01

Similar Documents

Publication Publication Date Title
JP7391038B2 (ja) Ｔｒｅｇ細胞の抑制特性を増強するための方法
CN114641564B (zh) 工程化的调节性t细胞
US20220363733A1 (en) Engineered regulatory t cell
US20250283039A1 (en) Method for maintaining suppressive activity of regulatory t cells

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220323

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230821

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231121

R150 Certificate of patent or registration of utility model

Ref document number: 7391038

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150